Drugs Made in America files Form 12b-25 for FY2025

Drugs Made in America Acquisition Corp. submitted a Form 12b-25 notifying the SEC it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Rhea-AI Filing Summary

Drugs Made in America Acquisition Corp. submitted a Form 12b-25 notifying the SEC it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company states it could not, without unreasonable effort or expense, compile required financial statements and expects to file on or before April 15, 2026.

Insights

Compliance Officer

Routine late-filing notice citing compilation delays; expected refiling date given.

The notice invokes Rule 12b-25 and explains the registrant could not timely compile the financial statements and related disclosures for the Form 10-K for the fiscal year ended December 31, 2025. The filing sets an expected delivery date of April 15, 2026.

Key dependencies include completion of audited financial statements and related disclosures. Subsequent SEC filings will confirm whether the 12b-25 cure occurred by the stated date.

Corporate Secretary

Administrative disclosure with contact and affirmative filing history answer.

The form lists Roger E. Bendelac as contact and signatory and indicates all other periodic reports required in the prior 12 months have been filed. This suggests the delay is isolated to the 2025 Form 10-K compilation.

Monitor the actual Form 10-K filing on or before April 15, 2026 to confirm resolution.

Key Figures

Form type: Form 12b-25 (NT 10-K) Period ended: December 31, 2025 Expected filing date: April 15, 2026 +2 more

5 metrics

Form type Form 12b-25 (NT 10-K) Notification of late filing for the Annual Report

Period ended December 31, 2025 Fiscal year end for the delayed Form 10-K

Expected filing date April 15, 2026 Date by which the registrant expects to file the Annual Report

Contact phone (917) 982-4565 Contact listed for inquiries (Roger E. Bendelac)

CUSIP G2847J104 CUSIP number shown on the notification

Key Terms

Rule 12b-25, Form 10-K, Notification of Late Filing

3 terms

Rule 12b-25 regulatory

"The reasons described in reasonable detail in Part III of this form"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-K regulatory

"Annual Report on Form 10-K for the fiscal year ended December 31, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

Notification of Late Filing regulatory

"NOTIFICATION OF LATE FILING"

A notification of late filing is a formal public statement that a company failed to submit a required regulatory report (for example, quarterly or annual financial statements) by the deadline. It matters to investors because missed filings can signal accounting, operational, or governance problems, may lead to fines or trading restrictions, and increases uncertainty about the company's transparency—like a public “we missed the deadline” flag that raises risk for shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Drugs Made in America (DMAA) file with the SEC?

The company filed a Form 12b-25 notification. It states the Form 10-K for the year ended December 31, 2025 could not be filed on time due to inability to compile required financial statements and disclosures.

When does DMAA expect to file its delayed Form 10-K?

DMAA expects to file the Annual Report on Form 10-K on or before April 15, 2026. The 12b-25 notice supplies that date as the cure timeline for the late filing.

Who signed the Form 12b-25 for DMAA and who is the contact?

The notice was signed by Roger E. Bendelac, Chief Executive Officer. He is also listed as the contact with phone number (917) 982-4565 for questions about the notification.

Does the filing indicate other periodic reports are late?

No. The form states that all other periodic reports required under Sections 13 or 15(d) during the preceding 12 months have been filed, indicating the delay relates only to the FY2025 Form 10-K.

Does DMAA anticipate a significant change in results in the delayed report?

The form answers No to whether a significant change in results from the prior year will be reflected, so no quantitative or narrative estimate of such a change is attached to the 12b-25 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

	FORM 12b-25	SEC FILE NUMBER
		001-42467
	NOTIFICATION OF LATE FILING	CUSIP NUMBER
		G2847J104

(Check One):	☒ Form 10-K	☐ Form 20-F	☐ Form 11-K	☐ Form 10-Q	☐ Form 10-D	☐ Form N-CEN
	☐ Form N-CSR

For Period Ended: December 31, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q

For the Transition Period Ended: _______________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

Full Name of Registrant:	Drugs Made in America Acquisition Corp.
Former Name if Applicable:	None
Address of Principal Executive Offices (Street and Number):	1 East Broward Boulevard
City, State and Zip Code	Suite 700 Fort Lauderdale, FL 33301

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Registrant expects to file the Annual Report on or before April 15, 2026.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Roger E. Bendelac		917		982-4565
Name		Area Code		Telephone Number

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Drugs Made in America Acquisition Corp.

(Name of Registrant as Specified in Charter)

has caused this to be signed on their behalf by the undersigned hereunto duly authorized.

Date: April 1, 2026	By:	/s/ Roger E. Bendelac
		Name:	Roger E. Bendelac
		Title:	Chief Executive Officer

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

3